Hinova Pharmaceuticals Inc. (688302.SS)
- Previous Close
38.14 - Open
38.11 - Bid 38.78 x --
- Ask 38.83 x --
- Day's Range
37.55 - 40.00 - 52 Week Range
23.11 - 43.40 - Volume
1,749,171 - Avg. Volume
2,380,289 - Market Cap (intraday)
3.955B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.05 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501, a product in phase II clinical trials for the treatment of hyperuricemia and gout; HP558, a product in phase II clinical trials to treat various late-stage cancers; and HP518, an oral PROTAC drug in phase I clinical trials with a focus on to solve the drug resistance of AR-mutated prostate cancer. Hinova Pharmaceuticals Inc. was founded in 2013 and is headquartered in Chengdu, China.
www.hinovapharma.comRecent News: 688302.SS
View MorePerformance Overview: 688302.SS
Trailing total returns as of 4/28/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 688302.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 688302.SS
View MoreValuation Measures
Market Cap
3.78B
Enterprise Value
2.94B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.32k
Price/Book (mrq)
3.17
Enterprise Value/Revenue
8.02k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-9.61%
Return on Equity (ttm)
-14.81%
Revenue (ttm)
366.84k
Net Income Avi to Common (ttm)
-184.38M
Diluted EPS (ttm)
-2.05
Balance Sheet and Cash Flow
Total Cash (mrq)
782.65M
Total Debt/Equity (mrq)
0.71%
Levered Free Cash Flow (ttm)
171.76M